Opinion
Video
The Role of PSA Doubling Time in Risk Assessment
Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.
EP: 1.Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer
EP: 2.Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
EP: 3.Evolving Treatment Paradigm and NCCN Guideline Updates
EP: 4.The EMBARK trial investigating enzalutamide in NM CSPC
Now Viewing
EP: 5.The Role of PSA Doubling Time in Risk Assessment
EP: 6.Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA
EP: 7.Patient Case 2: Metastatic CSPC
EP: 8.Final Thoughts on CSPC
- Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment?
- At what PSA doubling time thresholds do treatment recommendations change?
- How reliable is PSA doubling as a biomarker versus imaging or other tests?
Related Videos
Related Content
